

INTERCEPT PHARMACEUTICALS INC  
Form SC 13G/A  
February 10, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Amendment #1**

**Under the Securities and Exchange Act of 1934**

**Intercept Pharmaceuticals, Inc.**  
**(Name of Issuer)**

**Common Stock**  
**(Title of Class of Securities)**

**45845P108**  
**(CUSIP Number)**

**December 31, 2016**  
**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

This Schedule is filed pursuant to Rule 13d-1(b)

The information required in the remainder of this cover page (except any items to which the form provides a cross-reference) shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP NO. 45845P108

1) Name of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

Ameriprise Financial, Inc.

IRS No. 13-3180631

2) Check the Appropriate Box if a Member of a Group

(a)        (b)    \*

\* This filing describes the reporting person's relationship with other persons, but the reporting person does not affirm the existence of a group.

3) SEC Use Only

4) Citizenship or Place of Organization

Delaware

5) Sole Voting Power

NUMBER OF

SHARES        0

6) Shared Voting Power

BENEFICIALLY

OWNED BY        2,178,048

EACH        7) Sole Dispositive Power

REPORTING

PERSON        0

8) Shared Dispositive Power

WITH

2,507,900

9) Aggregate Amount Beneficially Owned by Each Reporting Person

2,507,900

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares

Not Applicable

11) Percent of Class Represented by Amount In Row (9)

10.11%

12) Type of Reporting Person

HC

CUSIP NO. 45845P108

1) Name of Reporting Person

S.S. or I.R.S. Identification No. of Above Person

Columbia Management Investment Advisers, LLC

IRS No. 41-1533211

2) Check the Appropriate Box if a Member of a Group

(a) (b) \*

\* This filing describes the reporting person's relationship with other persons, but the reporting person does not affirm the existence of a group.

3) SEC Use Only

4) Citizenship or Place of Organization

Minnesota

5) Sole Voting Power

NUMBER OF

SHARES 0  
6) Shared Voting Power

BENEFICIALLY

OWNED BY 2,178,048  
EACH 7) Sole Dispositive Power

REPORTING

PERSON 0  
8) Shared Dispositive Power

WITH

2,507,900

9) Aggregate Amount Beneficially Owned by Each Reporting Person

2,507,900

10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares

Not Applicable

11) Percent of Class Represented by Amount In Row (9)

10.11%

12) Type of Reporting Person

IA

- 1(a) Name of Issuer: Intercept Pharmaceuticals, Inc.
- 1(b) Address of Issuer's Principal: 450 W. 15th Street, Suite 505
- Executive Offices: New York, NY 10011
- 2(a) Name of Person Filing: (a) Ameriprise Financial, Inc. ( AFI )  
(b) Columbia Management Investment Advisers, LLC ( CMIA )
- 2(b) Address of Principal Business Office: (a) Ameriprise Financial, Inc.  
145 Ameriprise Financial Center  
Minneapolis, MN 55474  
(b) 225 Franklin St.  
Boston, MA 02110
- 2(c) Citizenship: (a) Delaware  
(b) Minnesota
- 2(d) Title of Class of Securities: Common Stock
- 2(e) Cusip Number: 45845P108

3 Information if statement is filed pursuant to Rules 13d-1(b) or 13d-2(b):

(a) Ameriprise Financial, Inc.

A parent holding company in accordance with Rule 13d-1(b)(1)(ii)(G). (Note: See Item 7)

(b) Columbia Management Investment Advisers, LLC

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

4 Incorporated by reference to Items (5)-(9) and (11) of the cover page pertaining to each reporting person. AFI, as the parent company of CMIA, may be deemed to beneficially own the shares reported herein by CMIA. Accordingly, the shares reported herein by AFI include those shares separately reported herein by CMIA.

Each of AFI and CMIA disclaims beneficial ownership of any shares reported on this Schedule.

5 Ownership of 5% or Less of a Class: Not Applicable

6 Ownership of more than 5% on Behalf of Another Person: Not Applicable

7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

AFI: See Exhibit I

8 Identification and Classification of Members of the Group:

Not Applicable

9 Notice of Dissolution of Group:

Not Applicable

10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.



Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 6, 2017

Ameriprise Financial, Inc.

By: /s/ Amy Johnson  
Name: Amy Johnson  
Title: Senior Vice President and Chief  
Operating Officer-Asset Management

Columbia Management Investment  
Advisers, LLC

By: /s/ Amy Johnson  
Name: Amy Johnson  
Title: Chief Operating Officer and Managing  
Director

Contact Information

Richard Dluzniewski  
Vice President-Control & Operational  
Risk-Operations and Investor Services  
Telephone: (212) 850-1434

Exhibit Index

- Exhibit I Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.
- Exhibit II Joint Filing Agreement